PharmaShots | Incisive News in 3 Shots

Subscribe Now

EC Approval

Samsung Bioepis' Byooviz (biosimilar- ranibizumab) Receives EC's Approval for the Treatment of Ophthalmic in EU

Samsung Bioepis' Byooviz (biosimilar- ranibizumab) Receives EC's Approval for the Treatment of Ophthalmic in EU

August 23, 2021

Bayer and Merck's Verquvo (vericiguat) Receives the EC's Approval for the Treatment of Chronic Heart Failure

Bayer and Merck's Verquvo (vericiguat) Receives the EC's Approval for the Treatment of Chronic Heart Failure

July 22, 2021

Bluebird Bio's Skysona (elivaldogene autotemcel) Receives EC's Approval for the Treatment of Cerebral Adrenoleukodystrophy

Bluebird Bio's Skysona (elivaldogene autotemcel) Receives EC's Approval for the Treatment of Cerebral Adrenoleukodystrophy

July 22, 2021

Merck's Keytruda (pembrolizumab) Receives the EC's Approval in Adults & Pediatric patients with R/R cHL

Merck's Keytruda (pembrolizumab) Receives the EC's Approval in Adults & Pediatric patients with R/R cHL

March 18, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us